New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:41 EDTRDUSRadius Health reports Q2 EPS ($2.22), may not compare to consensus (89c)
The net loss per share calculation for the three months ended June 30 includes the weighted average impact of Radius' convertible preferred stock converting into common stock upon the completion of its initial public offering in June. The decrease in net loss for the 2014 period was primarily due to a decrease in research and development expenses.
News For RDUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
08:12 EDTRDUSRadius Health shares can still reach $85, says Cantor
After Radius announced that it would delay filing for FDA approval of its abaloparatide drug by one quarter, Cantor thinks the decline in the stock was "excessive." The firm still believes that the drug's commercial opportunity along with the impact of other drugs from its pipeline, can drive the stock to $85. Cantor keeps an $85 price target and Buy rating on the shares.
November 17, 2015
08:34 EDTRDUSRadius Health submits MAA for abaloparatide
Radius Health announced that it has submitted a Marketing Authorization Application, or MAA, for an investigational, once-daily subcutaneous injection of abaloparatide, a novel synthetic peptide. In addition to other data, the MAA is supported by clinical studies exploring the use of abaloparatide for the treatment of women with postmenopausal osteoporosis, including the pivotal 18-month ACTIVE study which enrolled 2463 women. The announcement is being made during the company's Investor Day meeting being held today in New York City.
November 13, 2015
07:28 EDTRDUSRadius Health to host investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use